Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14255652 | 0.82 | SLC6A3 (0.48) | SLC6A3SLC6A4 | |
| SCHEMBL4874867 | 0.82 | SLC6A3 (0.48) | SLC6A3SLC6A4 | |
| SCHEMBL22917996 | 0.82 | SLC6A3 (0.48) | SLC6A3SLC6A4 | |
| SCHEMBL13698145 | 0.82 | SLC6A3 (0.48) | SLC6A3SLC6A4 | |
| SCHEMBL8208823 | 0.82 | SLC6A3 (0.48) | SLC6A3SLC6A4 | |
| SCHEMBL4026465 | 0.80 | SLC6A4 (0.42) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL729968 | 0.80 | SLC6A4 (0.55) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL730532 | 0.80 | SLC6A4 (0.55) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL734761 | 0.80 | SLC6A4 (0.55) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL28074497 | 0.79 | SLC6A3 (0.42) | SLC6A3SLC6A4SLC6A2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | CYP1B1, CYP2B6, CYP2D6 | SLC6A3 982/4885SLC6A4 2230/4885SLC6A2 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.